Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Can There Be Too Many Active Drugs?

Abstract

overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103-4108, 2009 12. Frances N, Claret L, Bruno R, et al: Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemother Pharmacol [epub ahead of print on April 8, 2011] 13. Stein WD, Gulley JL, Schlom J, et al: Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-917, 2011 14. Tham LS, Wang L, Soo RA, et al: A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine carboplatin in non-small cell lung cancer patients. Clin Cancer Res 14:4213-4218, 2008 15. Maitland ML, Hudoba C, Snider KL, et al: Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res 16:5296-5302, 2010 16. Yap TA, Sandhu SK, Workman P, et al: Envisioning the future of early anticancer drug development. Nat Rev Cancer 10:514-523, 2010 17. Bruno R, Lu JF, Sun YN, et al: A modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol 51:6-8, 2010 18. Barrett JS, Mondick JT, Narayan M, et al: Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak 8:6, 2008